Cynata Narrows Half-Year Loss but Faces Going Concern Uncertainty

Cynata Therapeutics Limited ( (AU:CYP) ) has issued an announcement.

Cynata Therapeutics reported revenue and other income of $1.77 million for the half-year to 31 December 2025, down about 10% from the prior corresponding period, while its loss after tax narrowed by 27% to $2.66 million. Despite an auditor’s review highlighting a material uncertainty over the group’s ability to continue as a going concern and a significant fall in net tangible asset backing per share, the accounts have been prepared on a going concern basis and no dividend was declared for the period.

The company’s net tangible asset backing per ordinary share dropped sharply to 0.70 cents from 4.21 cents a year earlier, underscoring pressure on its balance sheet. The board’s decision not to pay or recommend a dividend, combined with the going concern warning, indicates continued emphasis on conserving cash and funding ongoing development activities rather than returning capital to shareholders.

The most recent analyst rating on (AU:CYP) stock is a Hold with a A$0.41 price target. To see the full list of analyst forecasts on Cynata Therapeutics Limited stock, see the AU:CYP Stock Forecast page.

More about Cynata Therapeutics Limited

Cynata Therapeutics Limited is an Australian biotechnology company focused on developing cell-based therapies. Its operations center on therapeutic products that leverage proprietary technologies in the life sciences sector, with a market focus on advancing clinical-stage regenerative medicine treatments.

Average Trading Volume: 306,241

Technical Sentiment Signal: Buy

Current Market Cap: A$81.92M

Find detailed analytics on CYP stock on TipRanks’ Stock Analysis page.